NR1I3 antibody (AA 1-247)
Quick Overview for NR1I3 antibody (AA 1-247) (ABIN5013391)
Target
See all NR1I3 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 1-247
-
Purpose
- Polyclonal Antibody to Constitutive Androstane Receptor (CAR)
-
Specificity
- The antibody is a rabbit polyclonal antibody raised against CAR. It has been selected for its ability to recognize CAR in immunohistochemical staining and western blotting.
-
Cross-Reactivity
- Rat
-
Purification
- Antigen-specific affinity chromatography followed by Protein A affinity chromatography
-
Immunogen
- RPC422Mu01Recombinant Constitutive Androstane Receptor (CAR)
-
Isotype
- IgG
-
-
-
-
Application Notes
- Western blotting: 0.5-2 μg/mLImmunohistochemistry: 5-20 μg/mLImmunocytochemistry: 5-20 μg/mLOptimal working dilutions must be determined by end user.
-
Comment
-
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 500 μg/mL
-
Buffer
- 0.01M PBS, pH 7.4, containing 0.05 % Proclin-300, 50 % glycerol.
-
Preservative
- ProClin
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
-
-
- NR1I3 (Nuclear Receptor Subfamily 1, Group I, Member 3 (NR1I3))
-
Alternative Name
- Constitutive Androstane Receptor
-
Background
- NR1I3, NR1-I3, CAR1, MB67, Nuclear Receptor Subfamily 1,Group I,Member 3, Constitutive active response, Constitutive activator of retinoid response, Orphan nuclear receptor MB67
-
Pathways
- Nuclear Receptor Transcription Pathway, Intracellular Steroid Hormone Receptor Signaling Pathway, Steroid Hormone Mediated Signaling Pathway
Target
-